Abstract
Efficacy, safety and tolerability of a halobetasol 0.01%/tazarotene 0.045% fixed combination in the treatment of severe plaque psoriasis: Post hoc analysis of 2 phase III randomized controlled trials
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
